Unit:
Κατεύθυνση Σακχαρώδης Διαβήτης και ΠαχυσαρκίαLibrary of the School of Health Sciences
Author:
Panagopoulou Panagoula
Supervisors info:
Παπάνας Νικόλαος, Καθηγητής, Ιατρική, Δημοκρίτειο Πανεπιστήμιο Θράκης
Τεντολούρης Νικόλαος, Καθηγητής, Ιατρική, ΕΚΠΑ
Θανοπούλου Αναστασία, Επίκουρη Καθηγήτρια, Ιατρική, ΕΚΠΑ
Original Title:
Καρδιαγγειακή ασφάλεια και SGLT2 αναστολείς
Translated title:
Cardiovascular safety and SGLT2 inhibitors
Summary:
Epidemiological data suggest that type 2 diabetes mellitus significantly increases the risk of cardiovascular events. Therefore, when selecting antidiabetic medication to regulate the glycemic levels in patients with type 2 diabetes, it is important that the drugs do not increase this risk and ideally should reduce cardiovascular morbidity and mortality. The present bibliographic review investigates the association of SGLT2 inhibitors with cardiovascular disease and demonstrates their cardiovascular benefit. In the EMPA-REG OUTCOME and CANVAS studies, empagliflozine and canaglifosin respectively reduced significantly cardiovascular deaths in high-risk patients with type 2 diabetes mellitus. In addition, it’s being studied the literature on the proposed mechanisms through which SGLT2 inhibitors offer cardiovascular benefit.
Main subject category:
Health Sciences
Keywords:
Diabetes mellitus, SGLT2 inhibitors, Cardiovascular disease
